RxDoctor Payments Data

Joseph Rossi, MD

Interventional Cardiology · Sanford, NCNPI 1700074820

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $29,250 of the $43,133 with a category attached, or 67.8%. 22 manufacturers reported payments, led by Cardiovascular Systems Inc. at 56.0% of the total. Reporting peaked in 2019 at $10,498 and has fallen 66.1% since, to $3,561 in 2025.

$43,133in general payments, 2019–2025

Across 126 payments — averaging $342.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$24K
  • Abbott$8K
  • Angiodynamics, Inc.$3K
  • Inari Medical, Inc.$3K
  • Boston Scientific$2K
  • Abiomed$498
  • plus $3K from 16 others
$263,464in research payments, 2019–2025

Across 131 payments — averaging $2011.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inari Medical, Inc.$107K
  • Abbott$75K
  • Cardiovascular Systems Inc.$74K
  • Stryker$8K

What the payments were for

  • Speaking & faculty fees$29,25068%
  • Travel & lodging$6,44715%
  • Food & beverage$7,43717%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,133 in reported general payments places this provider in the 85th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$99,962
Medicare patients
388
Services billed
810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$131,932
Repatha SureclickEvolocumab46$54,725
XareltoRivaroxaban24$24,660
JardianceEmpagliflozin17$22,587
Ranolazine ErRanolazine30$2,566
Metoprolol Succinate155$2,319
Atorvastatin Calcium183$2,106
Ezetimibe122$2,063
Rosuvastatin Calcium101$1,874
ClopidogrelClopidogrel Bisulfate120$1,496
Losartan Potassium154$1,162
Isosorbide Mononitrate ErIsosorbide Mononitrate45$994
Nitroglycerin47$710
Lisinopril113$675
Carvedilol132$637

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Sanford

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →